This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.



MEDICINE JOURNAL

Breaking down the clotting conundrum: analyzing the role of plasma tissue plasminogen activator in COVID-19 patients through a systematic review and meta-analysis

Authors: Kacper Dziedzic, Mansur Rahnama-Hezavah, Monika Tomaszewska, Agnieszka Szarpak, Aleksandra Gasecka, Krzysztof Kuleta, Oliwia Fidali, Michal Pruc, Aleksander Ostenda, Magdalena Wierzbnik-Stronska, Aldona Kubica, Francesco Chirico

DOI: 10.5603/demj.97097

Article type: Research paper

Submitted: 2023-08-24

Accepted: 2023-08-30

Published online: 2023-09-14

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

BREAKING DOWN THE CLOTTING CONUNDRUM: ANALYZING THE ROLE OF PLASMA TISSUE PLASMINOGEN ACTIVATOR IN COVID-19 PATIENTS THROUGH A SYSTEMATIC REVIEW AND META-ANALYSIS

Kacper Dziedzic¹, Mansur Rahnama-Hezavah², Monika Tomaszewska¹, Agnieszka Szarpak³, Aleksandra Gasecka⁴, Krzysztof Kuleta⁴, Oliwia Fidali⁴, Michal Pruc^{5, 6}, Aleksander Ostenda⁷, Magdalena Wierzbnik-Stronska⁷, Aldona Kubica⁸, Francesco Chirico⁹

¹Department of Clinical Research and Development, LUX MED Group, Warsaw, Poland

²Chair and Department of Oral Surgery, Medical University of Lublin, Poland

³Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland

⁴1st Chair and Department of Cardiology, Medical University of Warsaw, Poland

⁵Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland

⁶Department of Public Health, International Academy of Ecology and Medicine, Kyiv, Ukraine ⁷Faculty of Medicine, Academy of Silesia, Katowice, Poland

⁸Department of Cardiac Rehabilitation and Health Promotion, *Collegium Medicum*, Nicolaus Copernicus University, Bydgoszcz, Poland

⁹Post-Graduate School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy

ADDRESS FOR CORRESPONDENCE:

Agnieszka Szarpak

Maria Sklodowska-Curie Medical Academy, Zelaznej Bramy Square 10, 00–136, Warsaw, Poland; e-mail: <u>a.szarpak@covinfo.pl</u>, phone: +48791221241

ABSTRACT

INTRODUCTION: The SARS-CoV-2 virus pandemic has been a global challenge for medical services in terms of patient care and early prognosis of hospitalized patients' situations. Early identification and classification of COVID-19 patients in hospitals is critical for optimal management. The purpose of this study is to compile existing data on tissue plasminogen activator (tPA) concentrations in COVID-19 patients.

MATERIAL AND METHODS: A systematic review and meta-analysis were carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. Qualified articles were found systematically using relevant databases such as PubMed Central, Scopus, EMBASE, and the Cochrane databases until May 4th, 2023.

RESULTS: Tissue plasminogen activator levels among COVID-19 positive vs negative patients T-PA levels among COVID-19 positive vs negative patients varied and amounted to 26.67 ± 40.65 vs 4.68 ± 3.83 , respectively (SMD = 2.49; 95% CI: 1.85 to 3.14; p < 0.001). The mean t-PA level among patients requiring ICU admission was 24.06 ± 12.44 , compared to 16.55 ± 10.01 for patients not treated in the ICU (SMD = 0.69; 95% CI: -0.68 to 2.05; p = 0.32). Moreover, t-PA levels among severe COVID-19 compared to non-severe were 11.89 ± 9.05 and 16.87 ± 20.39 , respectively (SMD = 2.74; 95% CI: -0.71 to 6.19; p = 0.12). The t-PA values were, respectively: 15.33 ± 8.01 for patients who survived hospital discharge, and 19.04 ± 11.88 for patients who died in hospital due to COVID-19 (SMD = -0.50; 95% CI: -2.45 to 1.44; p = 0.61).

CONCLUSIONS: According to this meta-analysis, the key conclusion of this study is that COVID-19 infection is connected to t-PA levels. Nonetheless, extensive prospective studies addressing the possible diagnostic relevance of t-PA as a marker of COVID-19 severity are required to corroborate the presented results.

KEYWORDS: tissue plasminogen activator; t-PA; COVID-19; SARS-CoV-2; coagulopathy

INTRODUCTION

Since 2019, the global healthcare system has faced a significant challenge in caring for patients and predicting outcomes due to the SARS-CoV-2 pandemic [1, 2]. There are many unknown pathomechanisms behind the complications of the virus, influencing disease severity, and mortality amongst the patients who received modified effective therapy [3]. Research emphasizes the significant role of the disturbed balance between the pro- and anticoagulant systems [4–9]. Even with prophylactic and therapeutic anticoagulation, thromboembolic complications are frequently observed [10, 11] along with markedly increased lysis resistance and prolonged diurnal lysis [12].

Many studies have focused on investigating the concentration of various biomarkers related to endothelial, inflammatory, and coagulation responses during COVID-19 [13–21]. The infection-induced pro-inflammatory environment results in endothelial dysfunction, which may lead to an imbalance between pro-coagulation and anti-coagulation factors. Elevated levels of tissue plasminogen activator (t-PA), and its inhibitor, plasminogen activation inhibitor 1 (PAI-1), fibrinogen, von Willebrand factor, as well as the receptor for interleukin-33, have been revealed in patients plasma. The combination of the biomarkers has also been evaluated as a prognostic factor for thrombosis and mortality [22]. More interestingly, despite the increased level of tPA, hypofibrinolysis as well as hypercoagulability have been observed [8]. The observations prompt further investigation into the impact of specific biomarkers on each other's activities and their influence on COVID-19 clinical outcomes.

Tissue-type plasminogen activator (tPA) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), are crucial components of the plasminogen activator-plasmin system [23, 24]. The imbalance between tPA and PAI-1 results in dysregulation of fibrinolysis and thrombotic complications [25]. Tissue plasminogen activator is the most extensively studied plasminogen activator and is commonly used clinically as a thrombolytic therapy [26]. The majority of diseases, including viral infections, impact the vascular endothelium and result in impaired function [27]. This endothelial dysfunction causes a decrease in the fibrinolytic activity of the cells, which increases the likelihood of developing blood clots [28].

Thromboembolic complications have the potential to be fatal, particularly in COVID-19 patients with a high risk of such events. It is crucial to evaluate possible risk factors that are predictors of disease progression and detect changes in the coagulation pathway. The purpose of this investigation is to review existing data on the concentration of tPA levels in COVID-19 patients and perform a meta-analysis to evaluate the correlation between tPA levels and COVID-19 disease, its severity, the likelihood of admission to the intensive care unit, and patients survival.

MATERIAL AND METHODS

This study was intended as a systematic review and meta-analysis and was carried out in compliance with the recommendations of the Cochrane Collaboration Group [29] and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standards (Table S1). [30]. This study protocol was submitted to PROSPERO (CRD42022380249).

Search strategy and study selection

Two independent reviewers (K.D. and M.P.) carried out the literature search. We searched PubMed Central, Scopus, EMBASE, and the Cochrane Collaboration Library for all relevant studies from January 2020 to May 4th, 2023. We used the phrases "tissue plasminogen activator" OR "t-PA" AND "SARS-CoV-2" OR "new coronavirus" OR "COVID-19" in our search. In addition, the reference lists of the included publications were manually examined for additional studies that were not found in the database search. EndNote X9 was used to import the titles and abstracts found in the database search (Clarivate Analytics, Philadelphia, USA).

Inclusion and exclusion criteria

The adopted inclusion criteria were as follows: (1) original articles; (2) COVID-19 patients in various clinical conditions: mild, moderate, severe, or critical; as well as COVID-19 patients who survive to hospital discharge or decreased; (4) all types of observational studies: cohort, cross-sectional, case-control, longitudinal; and (5) full-text articles available in English. The following were the exclusion criteria: (1) Studies that did not fit the aforementioned criteria; (2) Article types such as letters, conference papers, posters, editorials, review articles, and meta-analyses.

Data extraction

Two reviewers (M.P. and K.D.) independently evaluated the data extraction procedure, and disagreements concerning the selection criteria were argued and resolved by consensus among all authors. A predefined form was used to retrieve data from the included research.

Quality assessment

Three researchers (K.D., A.O., and M.P.) independently conducted the quality evaluation procedure. Any differences were also settled through discussion among all researchers. The Newcastle-Ottawa scale (NOS) was developed to assess the methodological quality of observational studies with its design. The studies were evaluated as poor, moderate, and high quality according to the NOS criteria, with ratings of 0–3, 4–6, and 7–9, respectively. In addition, if there are more than 10 trials in a single meta-analysis, we do funnel plot tests for asymmetry to evaluate potential publication bias.

Statistical analysis

The STATA software (version 14, StataCorp LLC, College Station, TX, USA) and the RevMan software (version 5.4, The Cochrane Collaboration, Copenhagen, Denmark) were used for all meta-analyses. To generate forest plots of continuous data and examine differences in t-PA concentrations between COVID-19 patients with severe vs non-severe groups or survivor vs non-survivor status during follow-up, standard mean differences (SMD) and 95% confidence intervals (CIs) were determined. A p-value of 0.05 was judged statistically significant. When t-PA levels were provided as medians with an interquartile range, Hozo's method for estimating means and standard deviations was utilized [31]. The p-value of the Q test and the I² statistic were used to assess study heterogeneity. A fixed-effects model was adopted since an I² of 50% was regarded as exhibiting low or moderate heterogeneity. We also ran a sensitivity analysis to evaluate how each study influenced the pooled estimate.

RESULTS

Study characteristics

Based on the above-mentioned inclusion criteria, we identified 1,548 reports and screened their summaries for eligibility after removing duplicates. 683 articles were screened according to their titles and abstracts. Full-text screening was performed on 27 studies, and data for 13 studies were extracted for this meta-analysis [4–6, 8–10, 12, 22, 25, 32–35]. A flow chart of

the literature search and study selection is presented in Figure 1. Among the included trials, nine studies reported the t-PA values among COVID-19 positive vs. negative patients. Four studies reported the correlation coefficient between t-PA concentration and ICU admission as well as COVID-19 survivability. In turn, three studies referred to the levels of t-PA between severe and non-severe courses of COVID-19.

The systematic review included articles published between 2020 and 2022, comprising a total of 948 COVID-19 participants. Baseline characteristics of selected studies are presented in Table 1. The study quality assessed by using the NOS scores was \geq 7 for all included trialtrials (Table 1).

Meta-analysis

Nine trials reported t-PA levels among COVID-19 positive vs. negative patients [4–6, 9, 12, 14, 22, 32, 35]. t-PA levels among those groups varied and amounted to 26.67 ± 40.65 vs 4.68 ± 3.83 , respectively (SMD = 2.49; 95% CI: 1.85 to 3.14; p < 0.001; Figure 2).

The mean t-PA level among patients requiring ICU admission was 24.06 ± 12.44 , compared to 16.55 ± 10.01 for patients not treated in ICU (SMD = 0.69; 95% CI: -0.68 to 2.05; p = 0.32; Figure S1) [5, 8, 12, 22]. Moreover, t-PA levels among severe COVID-19 compared to non-severe was 11.89 ± 9.05 and 16.87 ± 20.39 , respectively (SMD = 2.74; 95% CI: -0.71 to 6.19; p = 0.12; Figure S2) [9, 32, 35].

Only four trials reported t-PA levels in surviving and dead COVID-19 patients [25, 33, 34]. The t-PA values were respectively: 15.33 ± 8.01 for patients who survived to hospital discharge, and 19.04 ± 11.88 for patients who died in hospital due to COVID-19 (SMD = -0.50; 95% CI: -2.45 to 1.44; p = 0.61; Figure S3).

Discussion

In this systematic review and meta-analysis of 14 studies, including patients from 8 countries, we evaluated the serum t-PA levels of patients infected with COVID-19. Our aim was to assess its correlation with patients' clinical outcomes.

Due to the dramatic situation of patients as well as medical professionals' work overload during the COVID-19 pandemic, we consider it paramount to identify sensitive biomarkers supporting the diagnostics and treatment processes of the most severe patients. Such information might play a key role in the allocation of limited resources and therefore contribute to appropriate patient management. As hypercoagulability appears to be an essential hallmark of COVID-19 [36], evaluating markers of coagulation seems reasonable. Normally, there is an equilibrium between coagulation and fibrinolysis. Any imbalance between them might trigger serious conditions. Enhanced coagulation may lead, for instance, to thrombosis, stroke, or myocardial infarction, while hyperfibrinolysis might result in anomalous bleeding [37]. Furthermore, on histopathological examinations of lung specimens from COVID-19 patients with severe disease, fibrin-based occlusions of small vessels have been described as a result of increased blood coagulation [38, 39]. It is also proven that COVID-19 patients present not only hypercoagulability but also impaired fibrinolysis [8]. Coagulopathy in SARS-CoV-2 infection is multifactorial and accompanied by endothelial cell, neutrophil, and platelet activation, in addition to compensatory fibrinolysis. Various mechanisms have been suggested as the reason for coagulation disorders [9].

Changes in the equilibrium between the levels of t-PA and PAI-1 can indicate the procoagulant state brought on by endothelial activation [40]. t-PA is an enzyme responsible for the conversion of plasminogen into plasmin, which constitutes a part of the clot formation process. Despite being a fibrinolytic mediator, t-PA is found to be higher in COVID-19 patients with poor outcomes. This paradox may be explained by the contribution of PAI-1. PAI-1, a major inhibitor of t-PA, can be released from damaged endothelium simultaneously with t-PA [9]. Numerous studies mention an increased plasma level of PAI-1 in COVID-19 patients with poor outcomes [9, 12, 41]. High PAI-1 levels might overcome the fibrinolytic system despite the increased release of t-PA by facilitating the dissociation of t-PA from the surface of vascular endothelial cells (VES). Therefore, cell surface-associated fibrinolytic potential would be decreased [8, 42] and the state mentioned by Hammer as t-PA resistance would occur [12]. These hemostatic abnormalities are exacerbated by the severity of the disease and strongly correlate with proinflammatory status, demonstrating the link between coagulation and inflammation. Both t-PA and PAI-1 release are enhanced by proinflammatory stimuli [5] (Figure 3).

Recent studies have already described hypercoagulability and resistance to fibrinolysis [4]. It is worth mentioning that besides thrombosis, there is research that mentions bleeding events and literature data on hemorrhagic complications in COVID-19 patients during hospitalization [4, 5]. Extremely high levels of tPA enhance fibrinolysis and are associated with mortality in some individuals, which confirms the presence of a subset of patients that may favor fibrinolysis [6]. Since COVID-19 infection is associated with increased thrombotic

risk, prophylactic antithrombotic treatment has been highly recommended. We would like to pay attention to a subset of individuals who favor fibrinolysis and suggest targeted and individualized treatment based on the patient's clinical presentation and diagnostic findings. We believe that the risk of bleeding should always be taken into account. On the other hand, anticoagulant therapy alone might turn out to be less effective in decomposing fibrin clusters because of increased plasma levels of PAI-1 in COVID-19 patients, and more complex treatment may be required [22].

The results of our meta-analysis show the potential clinical role of tPA in patients with COVID-19. Results showed that tPA is significantly higher in COVID-19-positive individuals than in healthy individuals 26.67 ± 40.65 vs 4.68 ± 3.83 , respectively (p < 0.001). Considering that high levels of t-PA correlate with SARS-CoV-2 infection, this marker may potentially be a tool for the early identification of patients most likely to benefit from early antiviral therapy. Assessment of t-PA plasma levels may also be useful in identifying patients who might be at risk of enhanced fibrinolysis caused by extremely high t-PA levels, as mentioned before.

Our study shows the role of tPA in the prediction of ICU admission in patients with COVID-19. The mean t-PA level among patients requiring ICU admission was 24.06 \pm 12.44, compared to 16.55 \pm 10.01 for patients not treated in ICU (p = 0.32). This meta-analysis also shows the potential use of tPA as a prognostic marker of survival in patients with COVID-19. The t-PA values were respectively: 15.33 \pm 8.01 for patients who survived hospital discharge and 19.04 \pm 11.88 for patients who died in hospital due to COVID-19 (p = 0.61). However, we observed lower plasma concentrations of tPA in severe cases compared to non-severe COVID-19 positive cases (11.89 \pm 9.05 and 16.87 \pm 20.39; p = 0.12). Studies that do show significant plasma t-PA level differences between ICU and non-ICU patients [9] or between patients presenting severe and non-severe symptoms [10] have been performed; nevertheless, in our study, these differences didn't reach statistical significance. A biomarker cannot be translated into clinical practice and guidelines for treatment until it is proven to have a significant impact; therefore, the potential use of plasma t-PA levels as a biomarker of disease severity in COVID-19 needs further investigation.

Future studies about tPA concentration are needed to determine the cutoff points for clinical outcomes. This study should be valuable for the ongoing debate on coagulation biomarkers in COVID-19 since it analyzes and summarizes a set of research findings and comes up with conclusions based on the complex assessment of a large cohort.

Limitations

Our meta-analysis should be interpreted with caution due to some limitations. We included mostly prospective studies, which may constitute a risk of introducing bias. Additionally, hospital inpatients and those in critical care may have received higher prophylactic doses of thromboprophylaxis, potentially influencing test results. Other studies were limited by small sample sizes or could not provide longitudinal data. Enrollment of patients in different stages and severity of lung disease leads to heterogeneity, which may influence the interpretation of test results. Therefore, to confirm the findings presented, it is necessary to conduct thorough future studies that investigate whether t-PA can serve as a diagnostic indicator of the severity of COVID-19.

Conclusions

According to this meta-analysis, the key conclusion of this study is that COVID-19 infection is connected to t-PA levels. We indicated its potential usage as a COVID-19 biomarker and demonstrated its possible value in the diagnostic process. Nonetheless, extensive prospective studies addressing the possible diagnostic relevance of t-PA as a marker of COVID-19 severity are required to corroborate the presented results.

Article information and declarations

Data availability statement

The data that support the findings of this study are available on request from the corresponding author (A.S.).

Ethics statement

The data that support the findings of this study are available on request from the corresponding author (A.S.).

Author contributions

Conceptualization — K.D.; methodology — K.D. and M.P.; software — K.D., M.P and A.S.; validation — K.D., M.P., A.O. and A.S.; formal analysis — K.D., M.W.S. and A.S.; investigation — K.D.; resources — K.S. and L.S.; data curation — K.D., M.T., A.S., M.P. and M.W.S.; writing: original draft preparation — K.D., M.P., A.G., K.K., O.F., A.O.; writing: review and editing — K.D., M.R.H., M.T., A.S., A.G., K.K., O.F., M.P., A.K., A.O., M.W.S. and F.C.; visualization — K.D. and A.S.; supervision — K.D. and F.C; project administration — K.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://journals.viamedica.pl/disaster and emergency medicine/article/view/97097

References

- Dzieciatkowski T, Szarpak L, Filipiak KJ, et al. COVID-19 challenge for modern medicine. Cardiol J. 2020; 27(2): 175–183, doi: <u>10.5603/CJ.a2020.0055</u>, indexed in Pubmed: <u>32286679</u>.
- Tazerji SS, Shahabinejad F, Tokasi M, et al. Global data analysis and risk factors associated with morbidity and mortality of COVID-19. Gene Rep. 2022; 26: 101505, doi: <u>10.1016/j.genrep.2022.101505</u>, indexed in Pubmed: <u>35071820</u>.
- 3. Dubey L, Dorosh O, Dubey N, et al. COVID-19-induced coagulopathy: Experience, achievements, prospects. Cardiol J. 2023; 30(3): 453–461, doi: <u>10.5603/CJ.a2022.0123</u>, indexed in Pubmed: <u>36588310</u>.
- Whyte CS, Simpson M, Morrow GB, et al. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. J Thromb Haemost. 2022; 20(10): 2394–2406, doi: <u>10.1111/jth.15806</u>, indexed in Pubmed: <u>35780481</u>.
- Marchetti M, Gomez-Rosas P, Russo L, et al. Fibrinolytic proteins and factor XIII as predictors of thrombotic and hemorrhagic complications in hospitalized COVID-19 patients. Front Cardiovasc Med. 2022; 9: 896362, doi: <u>10.3389/fcvm.2022.896362</u>, indexed in Pubmed: <u>35757331</u>.
- **6.** Zuo Yu, Warnock M, Harbaugh A, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep. 2021; 11(1): 1580, doi: <u>10.1038/s41598-020-80010-z</u>, indexed in Pubmed: <u>33452298</u>.
- Ibañez C, Perdomo J, Calvo A, et al. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? J Thromb Thrombolysis. 2021; 51(2): 308–312, doi: <u>10.1007/s11239-020-02226-0</u>, indexed in Pubmed: <u>32671609</u>.
- 8. Nougier C, Benoit R, Simon M, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020; 18(9): 2215–2219, doi: 10.1111/jth.15016, indexed in Pubmed: 32668058.
- Francischetti IMB, Toomer K, Zhang Y, et al. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine. 2021; 39: 101069, doi: <u>10.1016/j.eclinm.2021.101069</u>, indexed in Pubmed: <u>34377969</u>.
- **10.** Kelliher S, Weiss L, Cullivan S, et al. Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. J Thromb Haemost. 2022; 20(4): 1008–1014, doi: <u>10.1111/jth.15660</u>, indexed in Pubmed: <u>35102689</u>.
- Gurbel PA, Tantry US, Storey RF. International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. J Thromb Thrombolysis. 2021; 52(4): 992–998, doi: <u>10.1007/s11239-021-02465-9</u>, indexed in Pubmed: <u>34021852</u>.
- 12. Hammer S, Häberle H, Schlensak C, et al. Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: a descriptive study of fibrinolysis in COVID-19. Thromb Haemost. 2021; 121(11): 1417–1426, doi: <u>10.1055/a-1400-6034</u>, indexed in Pubmed: <u>33634444</u>.
- **13.** Fialek B, De Roquetaillade C, Pruc M, et al. Systematic review with meta-analysis of midregional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients. Ann Med. 2023; 55(1): 379–387, doi: <u>10.1080/07853890.2022.2162116</u>, indexed in Pubmed: <u>36607317</u>.

- Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, et al. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Front Immunol. 2022; 13: 857573, doi: <u>10.3389/fimmu.2022.857573</u>, indexed in Pubmed: <u>35572561</u>.
- **15.** Kilic M, Hokenek UD. Association between D-dimer and mortality in COVID-19 patients: a single center study from a Turkish hospital. Disaster Emerg Med J. 2022; 7(4): 225–230, doi: <u>10.5603/demj.a2022.0039</u>.
- 16. Matuszewski M, Ładny J, Rafique Z, et al. Prediction value of soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients a systematic review and meta-analysis. Ann Agric Environ Med. 2023; 30(1): 142–147, doi: <u>10.26444/aaem/160084</u>, indexed in Pubmed: <u>36999867</u>.
- Matuszewski M, Szarpak L, Rafique Z, et al. Prediction value of KREBS von den lungen-6 (KL-6) biomarker in COVID-19 patients: a systematic review and meta-analysis. J Clin Med. 2022; 11(21), doi: <u>10.3390/jcm11216600</u>, indexed in Pubmed: <u>36362828</u>.
- Matuszewski M, Reznikov Y, Pruc M, et al. Prognostic performance of cystatin C in COVID-19: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022; 19(21), doi: <u>10.3390/ijerph192114607</u>, indexed in Pubmed: <u>36361485</u>.
- Kerget B, Kerget F, Koçak AO, et al. Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Lung. 2020; 198(5): 777–784, doi: <u>10.1007/s00408-020-00393-8</u>, indexed in Pubmed: <u>32918573</u>.
- 20. Fialek B, Pruc M, Smereka J, et al. Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis. Cardiol J. 2022; 29(5): 751–758, doi: <u>10.5603/CJ.a2022.0056</u>, indexed in Pubmed: <u>35762075</u>.
- 21. Fialek B, Yanvarova O, Pruc M, et al. Systematic review and meta-analysis of serum amyloid a prognostic value in patients with COVID-19. Disaster Emerg Med J. 2022; 7(2): 107–113, doi: <u>10.5603/demj.a2022.0021</u>.
- 22. Cabrera-Garcia D, Miltiades A, Yim P, et al. Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. Int J Hematol. 2022; 116(6): 937–946, doi: 10.1007/s12185-022-03437-2, indexed in Pubmed: 35994163.
- 23. Belen Apak FB, Yuce G, Topcu DI, et al. Coagulopathy is initiated with endothelial dysfunction and disrupted fibrinolysis in patients with COVID-19 disease. Indian J Clin Biochem. 2023; 38(2): 220–230, doi: <u>10.1007/s12291-023-01118-3</u>, indexed in Pubmed: <u>36816717</u>.
- 24. Douin DJ, Shaefi S, Brenner SK, et al. Tissue plasminogen activator in critically ill adults with COVID-19. Ann Am Thorac Soc. 2021; 18(11): 1917–1921, doi: <u>10.1513/AnnalsATS.202102-127RL</u>, indexed in Pubmed: <u>33872546</u>.
- **25.** Sehgal T, Gupta N, Kohli S, et al. A prospective study of specialized coagulation parameters in admitted COVID-19 patients and their correlation with acute respiratory distress syndrome and outcome. Cureus. 2021; 13(8): e17463, doi: <u>10.7759/cureus.17463</u>, indexed in Pubmed: <u>34589359</u>.
- **26.** Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost. 2015; 13 Suppl 1: S98–105, doi: <u>10.1111/jth.12935</u>, indexed in Pubmed: <u>26149056</u>.

- 27. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013; 9(10): 1057–1069, doi: <u>10.7150/ijbs.7502</u>, indexed in Pubmed: <u>24250251</u>.
- 28. Suzuki Y, Yasui H, Brzoska T, et al. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. Blood. 2011; 118(11): 3182–3185, doi: <u>10.1182/blood-2011-05-353912</u>, indexed in Pubmed: <u>21791417</u>.
- 29. Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.0 [updated 2019 Jul]. Cochrane:. <u>https://training.cochrane.org/handbook</u> (24.08.2023).
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71, doi: <u>10.1136/bmj.n71</u>, indexed in Pubmed: <u>33782057</u>.
- **31.** Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5: 13, doi: <u>10.1186/1471-2288-5-13</u>, indexed in Pubmed: <u>15840177</u>.
- 32. Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun. 2021; 116: 102560, doi: <u>10.1016/j.jaut.2020.102560</u>, indexed in Pubmed: <u>33139116</u>.
- **33.** Gualtierotti R, Tafuri F, Rossio R, et al. Lung ultrasound findings and endothelial perturbation in a COVID-19 low-intensity care unit. J Clin Med. 2022; 11(18), doi: <u>10.3390/jcm11185425</u>, indexed in Pubmed: <u>36143072</u>.
- 34. Ranucci M, Sitzia C, Baryshnikova E, et al. Covid-19-Associated coagulopathy: biomarkers of thrombin generation and fibrinolysis leading the outcome. J Clin Med. 2020; 9(11): 3487, doi: <u>10.3390/jcm9113487</u>, indexed in Pubmed: <u>33126772</u>.
- **35.** Damián-Vázquez G, García-Larragoiti N, Cano-Méndez A, et al. Recent findings on platelet activation, vWF multimers and other thrombotic biomarkers associated with critical COVID-19. Clin Applied Thrombosis/Hemostasis. 2022; 28: 1–10, doi: 10.1177/10760296221135792.
- **36.** Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(9): 2103–2109, doi: <u>10.1111/jth.14975</u>, indexed in Pubmed: <u>32558075</u>.
- **37.** Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015; 29(1): 17-24, doi: <u>10.1016/j.blre.2014.09.003</u>, indexed in Pubmed: <u>25294122</u>.
- 38. Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020; 8(7): 681–686, doi: <u>10.1016/S2213-2600(20)30243-5</u>, indexed in Pubmed: <u>32473124</u>.
- **39.** Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-422, doi: <u>10.1016/S2213-2600(20)30076-X</u>, indexed in Pubmed: <u>32085846</u>.
- **40.** Shapiro NI, Schuetz P, Yano K, et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care. 2010; 14(5): R182, doi: <u>10.1186/cc9290</u>, indexed in Pubmed: <u>20942957</u>.

- **41.** Suzuki Y, Mogami H, Ihara H, et al. Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood. 2009; 113(2): 470–478, doi: <u>10.1182/blood-2008-03-144279</u>, indexed in Pubmed: <u>18922856</u>.
- 42. Al-Farabi MJ, Nugraha RA, Marsudi BA, et al. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and metaanalysis. Microvasc Res. 2021; 138: 104224, doi: <u>10.1016/j.mvr.2021.104224</u>, indexed in Pubmed: <u>34273359</u>.




Figure 1. Flow diagram of the search strategy and study selection

	COVI	D-19	(+)	COV	D-19	(-)	9	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Cabrera-Garcia 2022	27.4	10.5	63	4.1	0.5	43	11.8%	2.85 [2.30, 3.40]	
Cugno 2021	37.9	18	50	11.3	8.5	27	11.8%	1.71 [1.17, 2.26]	-
Damián-Vázquez 2022	6.08	1.8	65	2.77	1.49	10	11.0%	1.86 [1.12, 2.59]	
Francischetti 2021	6.4	1.8	66	1.4	0.2	9	10.6%	2.91 [2.07, 3.76]	
Hammer 2021	3.3	1.2	28	1.3	0.4	11	10.6%	1.87 [1.05, 2.70]	
Kelliher 2022	7.4	0.9	14	4.3	0.4	11	7.7%	4.13 [2.65, 5.60]	
Marchetti 2022	21.5	5.7	101	5.8	1.6	108	12.1%	3.79 [3.34, 4.25]	-
Whyte 2022	4.2	0.5	113	2.5	0.9	54	12.2%	2.58 [2.15, 3.01]	-
Zuo 2021	78	68	118	2.4	2.6	30	12.2%	1.24 [0.81, 1.66]	-
Total (95% CI)			618			303	100.0%	2.49 [1.85, 3.14]	•
Heterogeneity: $Tau^2 = 0$.	,		,		0.000	001); I ²	= 91%	-	-4 -2 0 2 4
Test for overall effect: Z	= 7.56 (P < 0.	00001)						COVID-19 (+) COVID-19 (-)

Figure 2. Forest plot of tPA levels among COVID-19 positive vs. negative patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results




Figure 3. A visualization illustrating the effects of tPA

Study	Country	Study design	Study groups	No. of patients	Age	Sex, male	NOS
Cabrera-Garcia et	USA	Prospective cohort	ICU	47	61	28	8
al., 2022	ıl., 2022		Non-ICU	16	59	8	
			COVID-19 (+)	63	60 (55–69)	36	
			COVID-19 (-)	43	45 (30–61)	20	
Cugno et al., 2021	Italy	Single center	Severe	46	NS	NS	8
-		cohort study	Non-severe	102	NS	NS	
			COVID-19 (+)	148	63 (26–92)	87	
			COVID-19 (-)	27	55 (34–78)	19	
Damián-Vázquez	Mexico	Single center	Severe	28	53.5 (17.4)	23 (82.1)	8
et al., 2022		cohort study	Non-severe	37	44.7 (12.4)	19 (51.4)	
			COVID-19 (+)	65		42	
			COVID-19 (-)	10	46.2 (13.5)	7 (70.0)	
Francischetti et al.,	USA	Single center	Severe	26	66 (34–78)	14 (53.8)	8
2021		cross-sectional	Non-severe	40	47 (22–65.2)	19 (47.5)	
		study	COVID-19 (+)	66		33	
			COVID-19 (-)	9	47 (23–51)	5 (55.0)	
Gualtierotti et al.,	Italy	Single center	Survivors	57	68.2 (15.5)	34 (59.6)	7
2022		cohort study	Non-survivors	8	79.8 (5.6)	3 (37.5)	
Hammer et al.,	Germany	Retrospective	ICU	20	60 (55–75)	18	8
2021		observational	Non-ICU	9	44 (14–76)	4	
		descriptive study	COVID-19 (+)	29		22	
			COVID-19 (-)	11	38 (25–47)	6	
Kelliher et al.,	Ireland	Single center	COVID-19 (+)	14	69.7 (16.9)	7	8
2022		cohort study	COVID-19 (-)	11	61.6 (15.6)	3	
Marchetti et al.,	Italy	Two-center	ICU	46	62 (9)	35	8
2022		prospective study	Non-ICU	55	71 (12)	38	
			COVID-19 (+)	101	NS	NS	
			COVID-19 (-)	108	NS	NS	
Nougier et al.,	France	Retrospective	ICU	48	62.8 (13.1)	NS	7
2020		cohort study	Non-ICU	30	60.2 (14.6)	NS	
Ranucci et al.,	Italy	Prospective study	Survivors	8	59.6 (53.8–63.4)	7 (87.5)	8
2020	-		Non-survivors	12	69.4 (63.6–72.3)	9 (75.0)	

Table 1. Baseline characteristics of included trials

Sehgal et al., 2021	India	Prospective study	Survivors	59	NS	36	8
			Non-survivors	9	NS	7	
Whyte et al. 2022	UK	Prospective study	COVID-19 (+)	113	60.8 (12.6)	66 (58.4)	8
			COVID-19 (-)	24	64.4 (18.3)	10 (41.7)	
Zuo et al., 2021	USA	Prospective study	COVID-19 (+)	118	61 (17)	64	7
			COVID-19 (-)	30	NS	NS	

NOS — Newcastle Ottawa Scale; NS — not specified

Supplementary Material

		ICU		no	n-ICl	J		Std. Mean Difference	Std. Mean Difference					
Study or Subgroup	Mean SD Tota		Total	Mean	lean SD	Total	Weight	IV, Random, 95% CI		IV,	Rando	m, 95%	6 CI	
Cabrera-Garcia 2022	32.3	7.2	47	13	1.9	16	24.3%	3.01 [2.23, 3.80]					_	-
Hammer 2021	2.9	1.1	8	3.5	1.2	20	24.1%	-0.50 [-1.33, 0.34]			-	F		
Marchetti 2022	19.5	8	46	23.5	8.5	55	25.9%	-0.48 [-0.88, -0.08]			-			
Nougier 2020	23.9	14.5	48	14.4	7.5	30	25.7%	0.76 [0.29, 1.24]				-		
Total (95% CI)			149			121	100.0%	0.69 [-0.68, 2.05]						
Heterogeneity: Tau ² = 1.83; Chi ² = 67.83, df = 3 (P < 0.00001); $I^2 = 96\%$ Test for overall effect: Z = 0.98 (P = 0.32)										-2	ICU	0 Non-I	2	4

Figure S1. Forest plot of tPA levels among COVID-19 ICU vs non-ICU patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results

	Severe			Non	-seve	ere		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Cugno 2021	26.1	9.5	16	43.4	18.4	34	34.0%	-1.05 [-1.69, -0.42]] 🗕
Damián-Vázquez 2022	6.93	1.56	28	5.44	1.72	37	34.1%	0.89 [0.37, 1.41]] 🗕
Francischetti 2021	8.5	0.6	26	4.9	0.2	40	31.9%	8.76 [7.14, 10.38]	ı —
Total (95% CI)			70			111	100.0%	2.74 [-0.71, 6.19]	
Heterogeneity: Tau ² = 9. Test for overall effect: Z				f = 2 (P	< 0.0	0001);	$l^2 = 98\%$		-10 -5 0 5 10 Severe Non-severe

Figure S2. Forest plot of tPA levels among COVID-19 severe vs non-severe patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results

	Survive			Decrease			:	Std. Mean Difference	Std	Std. Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV	IV, Random, 95% CI				
Gualtierotti 2022	10.6	5.8	57	12.9	8.3	8	34.9%	-0.37 [-1.11, 0.37]		-	-			
Ranucci 2020	6.2	1.1	8	4.7	0.8	12	29.4%	1.55 [0.51, 2.59]			-	—		
Sehgal 2021	18.2	11.53	59	17.6	15.9	9	35.7%	0.05 [-0.65, 0.75]		-				
Total (95% CI)			124			29	100.0%	0.34 [-0.65, 1.33]						
Heterogeneity: Tau ² = Test for overall effect				= 2 (P	= 0.02	1); I ² =		-4 -2	0 Survive [Decrease	2	4		

Figure S3. Forest plot of tPA levels among COVID-19 surviving vs desceased patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results